Eris Lifesciences share news, announcements and annual reports
NSE: ERISBSE: 540596Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,156.40.
2 Nov: open ₹1,160.00, high ₹1,186.90, low ₹1,150.60
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,096 Cr353rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.75
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.88
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.62%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 19.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.58
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 45,47355.9% delivered
Eris Lifesciences share news and announcements
795 announcements, routine notices left out, newest first. Page 15 of 16.
Jun 2018
26 Jun · Analysts
25 Jun · Analysts
18 Jun · Analysts
12 Jun · Analysts
4 Jun · Analysts
1 Jun · Rating
May 2018
31 May · Analysts
28 May · Analysts
28 May · Analysts
25 May · Results
25 May · Board meeting
23 May · Analysts
1 May · Management
Apr 2018
25 Apr · Analysts
25 Apr · Analysts
21 Apr · Disclosure
19 Apr · Analysts
13 Apr · Analysts
Mar 2018
29 Mar · Analysts
27 Mar · Analysts
23 Mar · Analysts
21 Mar · Analysts
10 Mar · Analysts
7 Mar · Analysts
5 Mar · Analysts
5 Mar · Analysts
Feb 2018
21 Feb · Analysts
20 Feb · Management
19 Feb · Analysts
19 Feb · Legal
Exchange has sought clarification from Eris Lifesciences Limited with respect to announcement dated 13-Feb-2018, regarding " Eris Lifesciences Limited has informed the Exchange regarding Change in Auditors of the company.-Internal auditor". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment);The response of the Company is awaited.13 Feb · Management
12 Feb · Results
8 Feb · Analysts
2 Feb · Management
Jan 2018
24 Jan · Analysts
18 Jan · Analysts
9 Jan · Analysts
8 Jan · Analysts
2 Jan · Analysts
Dec 2017
19 Dec · Updates
18 Dec · Analysts